Supplier sign in
Home
STAY INFORMED
Subscribe to our monthly newsletter.
Your email address will never be disclosed to any third party.
Read our privacy notice.

   

COMPANY PAGE

Login
Latest update: 26.06.2025
Syngene International
Biocon Park, SEZ, Bommasandra Industrial Area, Phase-IV
 
India

Jigani Link Road
560099   Bangalore
India
Contact
Mr. Jonathan Hunt
Company video
Company brochure
Company brochure
Syngene is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies.
Syngene’s clients are world leaders in their fields, ranging from leading global multinationals to small and medium-sized start-ups, non-profit institutions, academic institutes and government organizations.

Incorporated in 1993, Syngene is listed separately on the Indian stock exchanges – NSE and BSE. With a unique business model, a talent pool of 5656 scientists, scientific expertise across new therapeutic modalities, an experienced management team, and an independent Board committee, Syngene works for clients around the globe, delivering innovation that benefits human and animal health. As a strategic partner to its clients, often working as an extension of their internal scientific teams, Syngene offers innovative, flexible, and efficient approaches to scale up rapidly. This, in turn, enables faster go-to-market and access to patients.


Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.

Adding to Syngene’s appeal as a partner of choice, is its strong corporate governance framework focused on client satisfaction, quality, safety, ethics, and data integrity. The entire business is underpinned by a robust global supply chain comprising 2900+ suppliers across 30 countries, including strong regional/local supplier networks to ensure uninterrupted supplies.

Syngene firmly believes in balancing business growth with responsibility towards the planet. Its environment social and governance (ESG) strategy is based on the key themes of managing its environmental footprint; being a responsible employer; ensuring strong governance; and investing in local communities. Syngene has invested in group captive in renewable and solar energy which has resulted in 82% of electricity consumed from renewable sources. We have achieved zero waste to landfill across all our sites. We have a zero liquid discharge policy at our sites in Bangalore and Mangalore
Products, services
CDMO Services, Sustaintability, Contract manufacturing,
Show more
Products, services
CDMO Services -
Sustaintability -
Contract manufacturing -

Articles

Green Chemistry is Quietly Reshaping the Way Medicines Are Made Alex Del Priore, SVP – Manufacturing Services
Green Chemistry is Quietly Reshaping the Way Medicines Are Made
Alex Del Priore, SVP – Manufacturing Services In recent years, green chemistry has begun to move from the margins of pharmaceutical development into its core. While sustainability has long been a talking point in the industry, practical integration into drug development has often lagged behind ambition. That is beginning to change. What was once dismissed as either impractical or idealistic is now showing commercial and operational value. With rising scrutiny of supply chains, tightening solvent regulations, and investor pressure around ESG disclosures, companies are finding that applying green chemistry principles can help them do more than reduce environmental impact—it can also lead to better processes, faster development timelines, and more resilient production models. This shift is playing out across every phase of the drug development lifecycle, from early-stage design to commercial-scale manufacture. In the past, sustainability was often considered late in the process, once the synthesis route had
18.08.2025  |  669x  | 
Sustainability is Becoming the Standard in Pharma Manufacturing
Alex Del Priore – Senior Vice President, Manufacturing Services. The pressure to reduce environmental impact is reshaping how pharmaceutical companies approach manufacturing. Sustainability is no longer a secondary consideration. It is becoming a core design requirement, shaping how processes are developed, scaled, and evaluated across the industry. At the heart of this transition is green chemistry, which is evolving from an aspirational goal into a practical, business-critical tool. Several forces are driving this shift. Fluctuating raw material costs, tightening solvent regulations, increasing scrutiny on waste generation, and the push for Scope 3 emissions reduction have converged. At the same time, the tools and frameworks available to support sustainable process redesign have matured significantly. What was once complex or experimental is now increasingly reliable, reproducible, and scalable in industrial settings. We recently saw these changes come together in a project with a global pharmaceutical partner. The company
09.07.2025  |  739x
PORTALS
Recycling-Portal Schuettgut-Portal BulkSolids-Portal
SIGN UP FOR OUR NEWSLETTER
Newsletter archive
Service and contact
ContactDisclaimerPrivacyAdvertising
FOLLOW US
Linked